Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
44 Heart Failure With Preserved Ejection Fraction Trials Near You
Power is an online platform that helps thousands of Heart Failure With Preserved Ejection Fraction patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerKetogenic Diet vs Mixed Diet for Heart Failure
Columbus, Ohio
This trial is comparing a ketogenic diet and a low-fat diet in people with heart failure and diabetes or related conditions. The goal is to see which diet improves exercise tolerance better. The ketogenic diet helps the body use fat for energy, while the low-fat diet focuses on reducing fat intake.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Type I Diabetes, Severe Kidney Disease, Others
90 Participants Needed
Ketone Supplement for Heart Failure
Columbus, Ohio
This study is being done to evaluate how a ketone ester (KE) beverage affects heart function and health in people with heart failure compared to a placebo beverage (a beverage made with standard food ingredients that do not contain ketone esters).
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Type I Diabetes, Severe Kidney Disease, Recent Myocardial Infarction, Others
Must Not Be Taking:SGLT2 Inhibitors
30 Participants Needed
Atrial Flow Regulator for Heart Failure
Columbus, Ohio
The purpose of this clinical study is to assess the safety and effectiveness of the Atrial Flow Regulator in the treatment of subjects, 18 years of age or older, who have symptomatic heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF) while on stable guideline directed medical therapy (GDMT) as outlined in the Guidelines for the Management of Heart Failure.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent MI, Stroke, Uncontrolled Hypertension, Others
Must Be Taking:Guideline Directed Medical Therapy
698 Participants Needed
CCM Therapy for Heart Failure
Columbus, Ohio
This trial tests a device that helps the heart pump better in patients with moderate heart failure. It targets those whose heart's pumping ability is moderately reduced. The device works by giving the heart small electrical boosts. Several new devices for the treatment of heart failure patients have been introduced and are increasingly used in medical practice or are under evaluation.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Dialysis, Cancer Treatment, Heart Surgery, Others
Must Be Taking:Loop Diuretics
1500 Participants Needed
Atrial Shunt Device for Heart Failure
Columbus, Ohio
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Advanced Heart Failure, Right Ventricular Dysfunction, Implanted Cardiac Device, Severe Depression, Others
Must Be Taking:Diuretics
750 Participants Needed
CK-4021586 for Heart Failure
Cincinnati, Ohio
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Malignancy, Active Infection, Others
Must Be Taking:Beta-blockers, ACE/ARB, SGLT2-inhibitors, GLP-1 Agonist
60 Participants Needed
JK07 for Heart Failure
Cincinnati, Ohio
This trial is testing a new medication called JK07 in people aged 18-85 who have heart failure. The study includes two groups based on how well their heart is pumping. Participants will receive either a low dose or high dose of JK07. The goal is to see if JK07 can improve heart function and help these patients feel better.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Stroke, Syncope, Others
Must Be Taking:Anticoagulants
282 Participants Needed
TX000045 for Pulmonary Hypertension
Toledo, Ohio
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 83
Sex:All
Key Eligibility Criteria
Disqualifiers:Significant Lung Disease, Cardiovascular, Others
Must Not Be Taking:Vasoactive Drugs
180 Participants Needed
Tovinontrine for Heart Failure
Cleveland, Ohio
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent HF Exacerbation, Acute Coronary Syndrome, Others
Must Be Taking:Guideline-directed HF Therapy
240 Participants Needed
Leg Heat Therapy for Heart Failure
Indianapolis, Indiana
The objective of this pilot study is to establish evidence to support the validity of HT in improving skeletal muscle function and physical capacity of patients with HFpEF. Our central hypothesis is that HT treatment will lead to improvements in skeletal muscle and microvascular function compared to a control intervention. As a result, we anticipate that patients treated with HT will demonstrate improved skeletal muscle microvascular blood flow and oxygenation resulting in enhanced exercise tolerance. To explore this hypothesis, we propose the following specific aim: Explore the effects of home-based HT on exercise tolerance in patients with HFpEF.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent Hospitalization, Unstable Angina, Renal Disease, Others
90 Participants Needed
Fiber Supplementation for Heart Failure
Ann Arbor, Michigan
The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome. The study team also wants to understand if adding potato starch to participant's diet helps these bacteria make more short chain fatty acids, a byproduct the team thinks may benefit participant's health.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Potato Allergy, Inflammatory Bowel Disease, Others
Must Not Be Taking:Antibiotics, Probiotics
30 Participants Needed
Respiratory Training for Heart Failure
Pittsburgh, Pennsylvania
In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage HF management.
* The study team hypothesize that older HF patients will be able to use IMT safely, reliably, and effectively in a 12-week home-based training regimen.
* The study team hypothesize that physical function (sit to stand, gait speed, grip strength), respiratory/pulmonary function, self-efficacy, fatigue and quality of life will increase among older HF patients randomized IMT versus those randomized to usual care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:70+
Sex:All
Key Eligibility Criteria
Disqualifiers:Dementia, Severe COPD, Anemia, Others
30 Participants Needed
High Fiber Diet + High-Intensity Exercise for Heart Failure
Charlottesville, Virginia
This study is trying to find out how best to improve common measures of health and survival in those diagnosed with heart failure with preserved ejection fraction (HFpEF) through the implementation of 4 weeks of an exercise training program consisting of high intensity interval training, dietary approaches to stop hypertension (DASH diet), or a combination of the two. Currently there are not established guidelines that have been shown to improve clinical end points in those with this HFpEF.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:40+
Sex:All
Key Eligibility Criteria
Disqualifiers:Unstable Angina, Myocardial Infarction, Others
36 Participants Needed
STM01 for Heart Failure
Chicago, Illinois
A Phase 1, Open label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypertrophic Cardiomyopathy, Atrial Fibrillation, Others
Must Be Taking:Heart Failure Therapy
12 Participants Needed
Dapagliflozin for Chronic Kidney Disease
Chicago, Illinois
This trial is testing dapagliflozin, a medication that helps remove sugar from the body through urine, in patients with chronic kidney disease and early heart failure. The study aims to see if this medication can improve their heart and lung function by lowering blood sugar levels. Dapagliflozin was initially approved for type 2 diabetes and later found to reduce cardiovascular and kidney problems.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Angina, Cancer, Others
Must Be Taking:Diuretics, ACE Inhibitors
60 Participants Needed
Metformin for Heart Failure
Winston-Salem, North Carolina
Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 80 older patients with heart failure with preserved ejection fraction (HFpEF).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:60+
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Hypertension, COPD, Cancer, Others
Must Not Be Taking:Antidiabetics, Antibiotics
80 Participants Needed
Physical Rehabilitation for Heart Failure
Winston-Salem, North Carolina
The REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility disability during 6-month follow-up in patients hospitalized for heart failure and preserved ejection fraction (HFpEF), which is nearly unique to older persons, and for which there are few treatment options.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Sex:All
Key Eligibility Criteria
Disqualifiers:Acute Myocardial Infarction, Severe Valvular Disease, Dementia, Others
Must Be Taking:Diuretics, Vasodilators
880 Participants Needed
Home-Based Cardiac Rehabilitation for Heart Failure
Nashville, Tennessee
The vast majority of individuals with heart failure do not participate in center based cardiac rehabilitation (CBCR). While steps to increase utilization of CBCR are important, many individuals will still not participate for a variety of reasons. This pilot randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients with heart failure. After a brief roll-in period, participants are randomized to one of two groups: (1) control or (2) HBCR mobile health intervention. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on physical activity, quality of life, clinical events, and other outcomes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Stage D Heart Failure, NYHA Class IV, Congenital Heart Disease, Pregnancy, Others
100 Participants Needed
Probiotic Supplement for Heart Failure
Milwaukee, Wisconsin
The goal of this study is to determine the impact of 12 weeks of Lp299v supplementation (20 million cfu/day vs. placebo) on exercise capacity, circulating biomarkers of cardiac remodeling, quality of life, and vascular endothelial function in humans with heart failure and reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) who have evidence of residual inflammation based on an elevated C-reactive protein level. This will be done in the setting of a randomized, double-blind, placebo-controlled trial.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Valve Disease, Cancer, Lung Disease, Others
Must Not Be Taking:Steroids, Anti-inflammatories, Antibiotics, Probiotics
20 Participants Needed
Sleep Extension for Heart Failure
Richmond, Virginia
Nearly one-third of US adults have poor sleep quality. Sleep quality refers to sleep efficiency, sleep latency, sleep duration, wake after sleep onset, and movement during the night. Specifically, sleep efficiency (SE) measures how well an individual utilizes their time in bed for restorative sleep and it highly depends on actual sleep duration. Reduced SE is associated with a greater risk for heart failure (HF), which affects \~6.7 million adults in the US alone. HF with preserved ejection fraction (HFpEF) accounts for about half of all HF diagnoses and is associated with poor prognosis (30-50% 5-year mortality from diagnosis) and severely reduced quality of life (QoL). Long-term goal for the investigators is to identify sleep modulation as a potential therapeutic target to improve QoL in HFpEF, with poor SE being present in \~60% of patients with HFpEF. The study is aimed to see if the sleep modulation is feasible and modulating sleep can improve the QoL and functional capacity along with the reduction of inflammation among subjects with HFpEF.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Diseases, Pregnancy, Insomnia, Others
Must Not Be Taking:Sleep Medicine, Melatonin
17 Participants Needed
Exogenous Ketone Drink for Heart Failure
Durham, North Carolina
The goal of this clinical research study is to test what effects a ketone drink will have in people with heart failure with preserved ejection fraction (HFpEF), including on exercise and heart function. Patients with HFpEF often have difficulty exercising, and our goal is to understand whether a ketone drink changes much patients can exercise. The study has three visits, including a baseline visit to assess for study eligibility, and two visits (one after 8 weeks of a ketone drink or a placebo drink, and another one after 8 weeks of whichever drink the participant did not receive the first time).
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cirrhosis, Diabetes, Pregnancy, Others
Must Not Be Taking:GLP-1 RAs
20 Participants Needed
Pacemaker Therapy for Heart Failure
Springfield, Illinois
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States. Data will be collected to evaluate whether pacing therapies can lead to improvements in exercise capacity and health status of subjects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Atrial Fibrillation, Structural Heart Disease, Severe COPD, Others
Must Be Taking:Heart Failure Medications
105 Participants Needed
Gene Therapy for Diastolic Heart Failure
Durham, North Carolina
This trial tests a new gene therapy for people with a type of heart failure where the heart struggles to relax and fill with blood. The therapy is given through an infusion directly into the heart. Researchers want to see if it helps the heart work better and if it is safe for patients. Gene therapy has shown promise in treating heart failure, with improvements making it safer and more effective.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Atrial Fibrillation, Severe COPD, Cancer, Others
Must Be Taking:Diuretics
10 Participants Needed
Cardiac Rehabilitation for Cardiac Amyloidosis
Charlotte, North Carolina
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:NYHA Class IV, Pulmonary Disease, Gait Instability, Others
50 Participants Needed
Empagliflozin + Potassium Nitrate for Heart Failure
Philadelphia, Pennsylvania
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Atrial Fibrillation, Valvular Disease, Cardiomyopathy, Others
Must Not Be Taking:Organic Nitrates, PDE Inhibitors
53 Participants Needed
Blood Flow Improvement Drugs + Supplements for Heart Failure
Philadelphia, Pennsylvania
This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Atrial Fibrillation, Others
Must Not Be Taking:Organic Nitrates, Phosphodiesterase Inhibitors
53 Participants Needed
Calcium Channel Blocker + Beta Blocker for Heart Failure
Philadelphia, Pennsylvania
Heart failure with preserved ejection fraction (HFpEF) is a critical public health problem. Heart failure (HF) affects over 5 million adults in the United States (US), and is a major source of morbidity, mortality, and impaired quality of life. Approximately half of individuals with HF have a preserved left ventricular (LV) ejection fraction (EF), termed HF with preserved EF (HFpEF). While there are several effective pharmacologic therapies for HF with reduced ejection fraction (HFrEF), none have been identified for HFpEF. Hypertension, which is present in approximately 80% of individuals with HFpEF, is the foremost modifiable risk factor for the development and progression of HFpEF. Despite the clinical importance of hypertension in HFpEF, there is limited information on how common antihypertensive agents, particularly calcium channel blockers (CCBs) and β-blockers, effect pathophysiologic mechanisms of HFpEF. This is a mechanistic investigation of the role of dihydropyridine CCBs compared to β-blockers (commonly used antihypertensive agents in clinical practice) in targeting key physiologic abnormalities in HFpEF.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:18 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Not Listed
50 Participants Needed
Transitions of Care for Heart Failure
Brick, New Jersey
The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. Patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multiple comorbidities. This project proposes to expand the existing Transitions of Care Clinic (TOCC) which was recently introduced in our institution in 2024, to bridge the gap in care between hospital discharge to home and connect discharged patients to their outpatient providers with a focus on patients with heart failure (HF).
The existing TOCC, a multidisciplinary team composed of a pharmacist and a nurse practitioner, seeks to improve the services that are currently being provided to patients and enhance the transitions of care process by providing patients with education, tools, and resources to help manage their chronic disease. With this study, we propose to expand TOCC by offering extensive education to patients via iPad videos and providing them with HF tool kits prior to their discharge. We will also assist with scheduling follow appointments with their outpatient providers and follow up with patients after the appointment takes place to re-evaluate their needs and reinforce self management of heart failure.
By targeting patients being treated for acute exacerbation of heart failure with preserved ejection fraction (HFpEF), this study aims to facilitate the transition of care, reduce hospital readmissions and improve patients' quality of life and satisfaction. Patients with HFpEF represent a majority of the HF patients that are readmitted at OUMC. HFpEF patients have fewer guideline recommended treatments and represent a vulnerable patient population. The HF tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate. Patients provided with a kit will receive an initial phone call from TOCC within 1 to 3 days of discharge and a second phone call within 21-24-days post discharge.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Dementia, Hemodialysis, Hospice, Others
150 Participants Needed
CHAT Program for Diastolic Heart Failure
New York, New York
The researchers are studying whether an intervention that involves video-based educational content and a health coach is acceptable, feasible, and effective for people with Heart Failure with Preserved Ejection Fraction (HFpEF).
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:60+
Sex:All
Key Eligibility Criteria
Disqualifiers:Not Listed
50 Participants Needed
Sotagliflozin for Heart Failure
New York, New York
The clinical benefits of the dual Sodium-Glucose cotransporter (SGLT) 1 and 2-inhibition have recently been reported in two clinical trials. The SOLOIST reported the benefits of sotagliflozin in Type-2 Diabetes Mellitus (T2DM) patients hospitalized for worsening of Heart Failure (HF), while the SCORED involved T2DM patients with Chronic Kidney Disease (CKD). It is worth noting that not only did the event curves separate within the first week post-treatment, but the effects of sotagliflozin on HF-related outcomes were observed regardless of Left Ventricular Ejection Fraction (LVEF) values and did not seem to attenuate with increasing LVEF as seen with empagliflozin and sacubitril/valsartan. Despite the favorable outcomes, the mechanism(s) of action through which sotagliflozin exerts these benefits remains unclear.
The present study aims to investigate the potential (non-glucose dependent) "cardio-renal" pleiotropic effects of sotagliflozin in a mechanistic, randomized, double blind, placebo-control trial in HF patients with preserved ejection fraction (HFpEF). Comparisons between treatment groups will be made using cardiac MRI, CPET, 6-MWT and KCCQ-12.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetes, Recent ACS, Low GFR, Others
Must Be Taking:Heart Failure Medications
60 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Heart Failure With Preserved Ejection Fraction clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do Heart Failure With Preserved Ejection Fraction clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Heart Failure With Preserved Ejection Fraction trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Heart Failure With Preserved Ejection Fraction is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a Heart Failure With Preserved Ejection Fraction medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest Heart Failure With Preserved Ejection Fraction clinical trials ?
Most recently, we added Exogenous Ketone Drink for Heart Failure, CHAT Program for Diastolic Heart Failure and Dapagliflozin for Fontan Circulation to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.